HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Section

Deals

M&A, licensing, and major transactions shaping the industry

In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory
DealsFiercePharma ↗
With Daiichi Sankyo’s priorities increasingly tied to its innovative medicines—and its oncology portfolio in p…
Apr 17, 2026
UCB Buys Neurona for $650M, Bets on Regenerative Medicine and Epilepsy Cell Therapy
DealsBriefing
UCB’s $650M-plus purchase of Neurona Therapeutics signals a move beyond small molecules into regenerative neur…
Apr 17, 2026
Novo Nordisk Bets on OpenAI to Accelerate Drug Development
DealsBriefing
Novo Nordisk unveiled a global AI collaboration with OpenAI, extending from drug discovery to manufacturing as…
Apr 17, 2026
Aligos Monetizes China Rights to HBV Drug in $445M Pact with Amoytop
Deals
Aligos sells Greater China rights to its phase 2 HBV drug for $25M upfront and up to $420M in milestones, as A…
Apr 17, 2026
Biovac gets $108M backing for vaccine factory in South Africa
DealsEndpoints News ↗
Biovac’s new vaccine factory in Cape Town, which is expected to make up to 400 million vaccines per year, has …
Apr 17, 2026
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions
DealsPharmaceutical Technology ↗
Daiichi Sankyo has partnered with Interna Therapeutics to develop targeted delivery solutions based on molecul…
Apr 17, 2026
← Newer Page 10 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.